



## Intrexon to Announce Third Quarter Financial Results on November 12th

November 4, 2019

### - Intrexon's subsidiary Precigen to host conference call to provide business and pipeline updates -

GERMANTOWN, Md., Nov. 4, 2019 /PRNewswire/ -- [Intrexon Corporation](#) (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release third quarter financial results before the market opens on Tuesday, November 12<sup>th</sup>, 2019. Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients and a wholly owned subsidiary of Intrexon, will host a conference call that day at 11:00 AM ET to provide Precigen business and pipeline updates.

The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada), and 1-412-317-6061 (International) and providing the number 4454504 to join the Precigen Business and Pipeline Update Call. Participants may also access the live webcast through Intrexon's website in the Investors section at <http://investors.dna.com/events> or Precigen's website in the Presentations section at <https://precigen.com/media/#id-presentations>.

### About Intrexon Corporation

Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet through two operating units – Intrexon Health and Intrexon Bioengineering. Intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. Intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, energy, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency. Our integrated technology suite provides industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at [www.dna.com](http://www.dna.com) or follow us on Twitter at [@Intrexon](#), on [Facebook](#), and [LinkedIn](#).

### About Precigen : Advancing Medicine with Precision™

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cellular therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Precigen also follows the science opportunistically in pursuit of promising programs in emerging therapeutics. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. Precigen was founded as a wholly owned subsidiary of [Intrexon Corporation](#) (NASDAQ: XON) and leverages a diverse portfolio of technology platforms to advance human health. For more information about Precigen, visit [www.precigen.com](http://www.precigen.com) or follow us on Twitter [@Precigen](#) and [LinkedIn](#).

### Trademarks

Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

### Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

<b>For more information contact:</b>	
<b>Intrexon Investor Contact:</b> Steven Harasym Vice President, Investor Relations Tel: +1 (301) 556-9850 <a href="mailto:investors@dna.com">investors@dna.com</a>	<b>Intrexon Corporate Contact:</b> Marie Rossi, PhD Vice President, Communications Tel: +1 (301) 556-9850 <a href="mailto:publicrelations@dna.com">publicrelations@dna.com</a>

<p><b>Precigen Media Contact:</b> Donelle M. Gregory <a href="mailto:press@precigen.com">press@precigen.com</a></p>	
---	--

SOURCE Intrexon Corporation; Precigen, Inc.